Literature DB >> 21050237

Comparison of balloon vs. straight catheter for the measurement of portal hypertension.

A Zipprich1, M Winkler, T Seufferlein, M M Dollinger.   

Abstract

BACKGROUND: The hepatic venous pressure gradient (HVPG) is used as an estimation of portal pressure (PP) in the management of patients with cirrhosis. Two methods are available using either a straight or a balloon catheter, but have never been compared head-to-head. AIM: To compare the two methods of determining HVPG, straight and balloon catheter, regarding reproducibility and reliability.
METHODS: In 47 patients with liver cirrhosis, HVPG was assessed using both catheters in sequence. In another 29 patients, the wedged hepatic venous pressure (WHVP) determined either with straight or balloon catheter was correlated with a direct measurement of PP. Variation coefficient and intraclass correlation coefficient were calculated.
RESULTS: Variation coefficients for balloon catheter were 0.07 (HVPG), 0.02 (WHVP) and 0.06 [free hepatic venous pressure (FHVP)]. Variation coefficients for straight catheter were 0.17 (HVPG), 0.06 (WHVP) and 0.07 (FHVP), demonstrating a significantly wider variation of the HVPG and WHVP measurements (P < 0.001). Comparison of WHVP with PP revealed a correlation coefficient of 0.72 (P = 0.004) using balloon catheter and 0.58 (P = 0.011) using straight catheter.
CONCLUSIONS: Measurements with the balloon catheter currently represent the most reliable and reproducible method to assess HVPG. The results are of particular clinical relevance if repeated measurements are required for therapeutic adjustments.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21050237     DOI: 10.1111/j.1365-2036.2010.04484.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

2.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

3.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

4.  Comparison of hepatic venous pressure gradient and endoscopic grading of esophageal varices.

Authors:  EunJi Lee; Yong Jae Kim; Dong Erk Goo; Seung Boo Yang; Hyun-Joo Kim; Jae Young Jang; Soung Won Jeong
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

5.  Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein.

Authors:  Akira Yamamoto; Norifumi Kawada; Atsushi Jogo; Kazuki Murai; Kohei Kotani; Ken Kageyama; Shinichi Hamamoto; Etsuji Sohgawa; Sawako Uchida-Kobayashi; Masaru Enomoto; Akihiro Tamori; Yukio Miki
Journal:  Gut       Date:  2020-08-18       Impact factor: 23.059

6.  Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Authors:  Thomas Reiberger; Andreas Püspök; Maria Schoder; Franziska Baumann-Durchschein; Theresa Bucsics; Christian Datz; Werner Dolak; Arnulf Ferlitsch; Armin Finkenstedt; Ivo Graziadei; Stephanie Hametner; Franz Karnel; Elisabeth Krones; Andreas Maieron; Mattias Mandorfer; Markus Peck-Radosavljevic; Florian Rainer; Philipp Schwabl; Vanessa Stadlbauer; Rudolf Stauber; Herbert Tilg; Michael Trauner; Heinz Zoller; Rainer Schöfl; Peter Fickert
Journal:  Wien Klin Wochenschr       Date:  2017-10-23       Impact factor: 1.704

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.